Pembrolizumab with salvage chemotherapy for Hodgkin lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 study tests whether pembrolizumab combined with salvage (second-line) chemotherapy can treat people whose classical Hodgkin lymphoma has either come back after initial treatment or did not respond to initial treatment. You may benefit if you have first-relapsed or refractory classical Hodgkin lymphoma and meet other study rules.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have classical Hodgkin lymphoma confirmed by biopsy (tissue testing).
- Your disease is either your first relapse, or it did not respond to initial treatment.
- Your diagnosis is not nodular lymphocyte-predominant Hodgkin lymphoma.
- Your diagnosis is not a composite lymphoma type.
- You must be eligible for the study’s combination treatment approach with pembrolizumab and salvage chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines an immunotherapy drug (a type of treatment that helps your immune system fight cancer) with radiation therapy for people with early-stage classic Hodgkin lymphoma. The goal is to see if this combination can treat the cancer effectively while possibly reducing side effects.
This study tests whether combining the immunotherapy drug pembrolizumab (Keytruda) with the chemotherapy bendamustine can help people with Hodgkin lymphoma whose cancer returned or did not respond to earlier treatment. The goal is to see if this two-drug combination works better than either drug alone.
This trial tests a drug called pembrolizumab as the first treatment for advanced-stage classical Hodgkin lymphoma. It may help shrink tumors and keep the disease from getting worse.
This Phase 2 study tests azacitidine together with pembrolizumab in people whose Hodgkin lymphoma has come back or did not respond (relapsed/refractory). It aims to see whether this combination can control cancer and improve outcomes, especially when standard high-dose chemotherapy is not an option.
This study tests a combination of the immunotherapy drug pembrolizumab with a chemotherapy regimen called GVD for patients whose Hodgkin's lymphoma has not responded or has returned after initial treatment. The goal is to see if this combination works better than standard approaches.
This Phase 2 trial tests whether pembrolizumab plus brentuximab works better than standard chemotherapy followed by an autologous stem cell transplant for people whose classic Hodgkin lymphoma has come back or did not respond. It may help by improving cancer control before and around stem cell transplant and by comparing outcomes between the two treatment approaches.
Hear when a new Classical Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.